查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012553

人工尿道括約肌市場：按類型、性別、分銷管道、應用和最終用戶分類－2026年至2032年全球市場預測

Artificial Urinary Sphincters Market by Type, Gender, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工尿道括約肌市場價值將達到 4.6099 億美元，到 2026 年將成長至 4.9751 億美元，到 2032 年將達到 7.6318 億美元，年複合成長率為 7.46%。

主要市場統計數據
基準年 2025 460,990,000 美元
預計年份：2026年 4.9751億美元
預測年份 2032 7.6318億美元
複合年成長率 (%) 7.46%

人工尿道括約肌權威指引：系統性地說明了臨床必要性、設備發展歷程以及醫療系統和設備開發人員的策略考量。

人工尿道括約肌（AUS）在泌尿系統、外科醫療設備創新和以患者為中心的排尿管理領域佔據著策略性的關鍵地位。這些器械最初旨在幫助應力性尿失禁和神經源性膀胱功能障礙患者恢復排尿控制能力，並隨著材料科學、外科技術和門診護理模式的進步而不斷發展。臨床需求顯而易見：恢復可靠的排尿功能能夠顯著提高患者的生活品質，減輕看護者的負擔，並減少持續性尿失禁患者長期照護的需求。

隨著臨床實踐、設備工程和護理服務模式的融合，關鍵趨勢正在重塑人工尿道括約肌領域，並影響人工尿道括約肌的普及應用。

人工尿道括約肌領域正經歷一場變革，這得益於臨床、技術和治療模式三方面因素的融合。首先，隨著臨床醫師採用更嚴格的表現型分析和共用決策框架，患者選擇標準日趨成熟，長期治療效果不斷提升，再次手術率持續下降。其次，器械工程正朝著模組化和材料改良的方向發展，透過簡化手術技巧，縮短了外科醫師進行植入手術的學習曲線，同時最大限度地減少了侵蝕和感染的風險。

對2025年生效的美國關稅對尿道括約肌相關人員的供應鏈策略、生產本地化和採購決策的影響的實用分析

美國計劃於2025年實施的關稅為涉及相關人員尿道括約肌等醫療設備的供應鏈和採購決策帶來了新的不穩定性。關稅帶來的成本壓力尤其影響海外生產的器械和零件的籌資策略。因此，製造商正在重新評估其供應商名單，以降低關稅上漲帶來的風險，並在保持價格競爭力的同時維持利潤率，從而吸引醫療服務提供者。

詳細的細分分析解釋了醫療設備類型、最終用戶環境、分銷管道、性別差異和臨床應用如何共同影響商業化和臨床應用。

市場區隔洞察揭示了決定人工尿道括約肌臨床適用性、商業化策略和分銷複雜性的關鍵因素。根據類型，該領域可分為單組件、三組件和雙組件設計，每種設計都代表不同的手術流程、再次手術風險以及對植入醫生的培訓要求。單組件系統傾向於優先考慮簡便性，而三組件解決方案則在可調節性和生理模擬性之間尋求平衡，雙組件則探索了器械複雜性和手術效率之間的折衷方案。

一份全面的區域分析報告，描述了美洲、歐洲、中東和非洲以及亞太地區在設備部署的臨床、監管和商業性路徑上的差異。

人工尿道括約肌的區域趨勢各不相同，並受到全球主要市場醫療基礎設施、報銷機制和手術實施模式的影響。在美洲，先進的泌尿系統護理、大量的門診手術以及保險公司對長期治療效果和成本效益的重視，正在塑造著人工尿道括約肌的普及趨勢。該地區的臨床醫生通常在產生比較性臨床證據和製定最佳實踐手術方案方面發揮主導作用，這反過來又會影響商業策略和產品定位。

關鍵的公司層面洞察揭示了臨床證據、製造策略、培訓計劃和策略夥伴關係如何在尿道括約肌市場中創造永續的差異化優勢。

在人工尿道括約肌領域，各公司之間的競爭格局主要體現在透過臨床證據、器械可靠性、手術可操作性和綜合支持服務實現差異化。主要企業優先考慮長期療效數據、外科醫生培訓項目和上市後監測，以證明產品的耐用性和安全性。此外，投資於微創植入技術和簡化操作機制的公司可以縮短手術時間，並擴大可進行植入手術的臨床醫生群體。

為醫療器材製造商和醫療保健系統提供策略和營運建議，以建立臨床證據，從而加速部署、保護利潤率並支持採購決策。

產業領導企業應推動一系列務實舉措，以平衡臨床價值、永續的商業性收入和營運韌性。首先，他們應優先透過註冊登記和多中心觀察性研究產生高品質的真實世界數據 (REW) 和病患報告結局 (PRO)，以支持其價值主張，並有助於與支付方和醫院採購團隊進行談判。其次，他們應最佳化器械設計和包裝，以縮短手術時間並簡化庫存管理，從而贏得門診手術中心和高周轉率診所的支援。

為了支持研究結果，我們需要對研究途徑進行透明的解釋，該方法結合了臨床文獻的整合、與相關人員的訪談、治療流程圖繪製和供應鏈情境分析。

本報告的調查方法結合了系統性文獻綜述、相關人員訪談、醫療設備流程圖繪製以及監管和支付框架的整合，旨在建立穩健的證據基礎進行分析。研究人員對臨床文獻和指南資訊來源進行了交叉檢驗，並結合對植入外科醫生、採購經理和分銷合作夥伴的訪談，深入了解實際決策因素和營運限制。流程圖繪製記錄了門診手術中心、診所和醫院的具體需求，從而能夠評估醫療設備的適用性和手術全期資源需求。

總之，綜合分析強調了臨床證據、設備設計和供應鏈韌性之間的關鍵交互作用，這決定了長期的成功和對患者的影響。

總之，人工尿道括約肌仍然是臨床上至關重要的治療方法，隨著器材創新、證據累積和醫療服務模式的轉變，其應用前景也日益廣闊。未來的普及取決於製造商能否證明其產品具有持續的臨床療效，設計出能夠簡化手術流程的植入，並調整經營模式以適應不同終端用戶環境下的採購實際情況。價格壓力和供應鏈風險凸顯了營運柔軟性和策略性供應商選擇的重要性，以維持市場准入和競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 人工尿道括約肌市場：依類型分類

  • 單組分
  • 3個組成部分
  • 2 個組件

第9章 人工尿道括約肌市場：性別

  • 女士
  • 男性

第10章：人工尿道括約肌市場：依通路分類

  • 直銷
    • 我們的銷售團隊
    • OEM銷售團隊
  • 銷售代理
    • 線上平台
    • 第三方經銷商

第11章 人工尿道括約肌市場：依應用領域分類

  • 神經源性膀胱功能障礙
  • 應力性尿失禁

第12章：人工尿道括約肌市場：依最終用戶分類

  • 門診手術中心
    • 獨立的
    • 醫院附屬機構
  • 診所
    • 全科診所
    • 泌尿系統診所
  • 醫院
    • 私立醫院
    • 公立醫院

第13章 人工尿道括約肌市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 人工尿道括約肌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 人工尿道括約肌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：人工尿道括約肌市場

第17章 中國：人工尿道括約肌市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Affluent Medical
  • Albyn Medical Ltd.
  • Andromeda Medizinische Systeme GmbH
  • Anhui Longterm Medical Products Co., Ltd.
  • Boston Scientific Corporation
  • Coloplast A/S
  • CooperSurgical Inc.
  • Dualis MedTech GmbH
  • GT Urological LLC
  • LABORIE Medical Technologies Inc.
  • MyoPowers Medical Technologies SAS
  • Promedon SA
  • Rigicon Inc.
  • Uromedical AG
  • Zephyr Surgical Implants AG
Product Code: MRR-432CBFF6F3AA

The Artificial Urinary Sphincters Market was valued at USD 460.99 million in 2025 and is projected to grow to USD 497.51 million in 2026, with a CAGR of 7.46%, reaching USD 763.18 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 460.99 million
Estimated Year [2026] USD 497.51 million
Forecast Year [2032] USD 763.18 million
CAGR (%) 7.46%

A definitive introduction to artificial urinary sphincters that frames clinical imperatives, device evolution, and strategic considerations for health systems and device developers

Artificial urinary sphincters (AUS) occupy a strategic intersection between urology, surgical device innovation, and patient-centered continence management. Historically designed to restore urinary control for patients affected by stress urinary incontinence and neurogenic bladder dysfunction, these devices have evolved in parallel with advances in materials science, surgical technique, and outpatient care models. The clinical imperative is clear: reliable continence restoration materially improves quality of life, reduces caregiver burden, and decreases long-term care needs for patients with persistent incontinence.

Clinicians now approach device selection with a more nuanced appreciation of patient phenotype, device ergonomics, and the downstream implications for infection prevention and revision procedures. Consequently, manufacturers are competing not only on implant performance but on ease of implantation, postoperative management pathways, and integrated training for surgeons. From a stakeholder perspective, hospitals and ambulatory surgical centers are evaluating the total cost of care implications of AUS implantation, weighing upfront procedural resource requirements against long-term reductions in incontinence-associated therapies and readmissions.

Transitioning from legacy devices to newer designs requires evidence that addresses safety, durability, and patient-reported outcomes in real-world settings. As a result, cross-functional teams spanning clinical research, regulatory affairs, and commercial operations must align to accelerate adoption. In this context, the introduction to artificial urinary sphincters is best framed as an ongoing process of clinical validation, health system integration, and iterative device refinement that will shape adoption trajectories over the coming years.

Critical transformative trends reshaping the artificial urinary sphincter landscape as clinical practice, device engineering, and care delivery models converge to influence adoption

The landscape for artificial urinary sphincters is undergoing transformative shifts driven by converging clinical, technological, and delivery-model forces. First, patient selection has matured as clinicians adopt more rigorous phenotyping and shared decision-making frameworks, which improves long-term outcomes and reduces revision rates. Second, device engineering has moved toward modularity and refinement of materials to minimize erosion and infection while simplifying surgical technique, thereby shortening learning curves for implanting surgeons.

Concurrently, the rise of ambulatory surgical centers and their increasing role in elective urological procedures is reshaping procedure economics and perioperative protocols. These sites demand devices that enable efficient implantation and predictable recovery pathways. Moreover, digital health integration is beginning to influence postoperative monitoring, enabling remote collection of patient-reported outcomes and early detection of complications, which supports safer outpatient management.

Regulatory pathways are also evolving, with greater emphasis on post-market surveillance and real-world evidence to demonstrate device safety and effectiveness. This shift encourages manufacturers to invest in longitudinal registries and robust evidence generation strategies. Finally, payer and hospital procurement stakeholders now place higher priority on demonstrable improvements in quality metrics and reductions in downstream resource utilization. Together, these shifts create an environment in which clinical evidence, surgical ergonomics, and delivery-site fit determine winners and laggards in the AUS ecosystem.

Practical analysis of how the United States tariffs effective in 2025 influence supply chain strategies, production localization, and procurement decisions for urinary sphincter stakeholders

The imposition of United States tariffs scheduled for 2025 has introduced a new variable into supply chain and procurement decision-making for medical device stakeholders involved with artificial urinary sphincters. Tariff-driven cost pressures affect component sourcing strategies, especially for devices or subcomponents produced internationally. As a consequence, manufacturers are reassessing supplier footprints to mitigate exposure to tariff escalations and to preserve margin while maintaining competitive pricing for healthcare providers.

In response, some device firms are accelerating near-shoring initiatives, shifting assembly or critical component production closer to core markets to reduce tariff pass-through and improve supply-chain resilience. Others are pursuing strategic supplier diversification to avoid single points of failure and to gain leverage in contract negotiations. Hospitals and ambulatory surgical centers are also adjusting procurement practices, engaging in more rigorous total cost of ownership assessments that incorporate potential tariff variability and logistics risk premiums.

Importantly, tariff-related shifts ripple beyond direct cost implications. Manufacturers with vertically integrated supply chains or flexible production capacity will find it easier to absorb or offset tariff impacts, whereas smaller suppliers may face margin compression that limits their ability to invest in product improvements or evidence generation. In turn, clinicians and health systems should expect to see a gradual repricing of devices, a recalibration of distributor contracts, and a stronger focus on long-term value metrics when negotiating purchasing agreements in the post-tariff environment.

Deep segmentation analysis explaining how device type, end-user settings, distribution channels, gender differences, and clinical applications jointly shape commercialization and clinical adoption

Segmentation insights reveal critical levers that determine clinical fit, commercialization tactics, and distribution complexity for artificial urinary sphincters. Based on Type, the field differentiates among Single Component, Three Component, and Two Component designs, each presenting distinct surgical workflows, revision risk profiles, and training needs for implanting clinicians. Single component systems often emphasize simplicity, while three component solutions aim to balance adjustability and physiological mimicry, and two component variants seek compromise between device complexity and procedural efficiency.

Based on End User, adoption dynamics vary across Ambulatory Surgical Centers, Clinics, and Hospitals. Ambulatory Surgical Centers are further differentiated into Freestanding and Hospital Affiliated models, both of which prioritize throughput and predictable perioperative pathways. Clinics are categorized into Multispecialty Clinics and Urology Clinics, and these settings influence referral patterns, patient counseling practices, and follow-up care models. Hospitals, divided into Private Hospitals and Public Hospitals, bring differing procurement governance, purchasing cycles, and risk tolerance that affect device selection and contract negotiations.

Based on Distribution Channel, strategies range from Direct Sales to Distributors. The Direct Sales route includes In House Sales Force and OEM Sales Force approaches that enable tighter clinical training and closer customer relationships, whereas Distributors encompass Online Platforms and Third Party Distributors that provide broader geographic reach and logistical scale. Based on Gender, device uptake, surgical approach, and rehabilitative needs vary across Female and Male patient groups, prompting manufacturers to tailor design considerations and outcome measurement. Finally, based on Application, clinical use cases separate into Neurogenic Bladder Dysfunction and Stress Urinary Incontinence, with each indication driving different evidence requirements, patient management pathways, and reimbursement conversations.

Comprehensive regional intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct clinical, regulatory, and commercial pathways for device adoption

Regional dynamics for artificial urinary sphincters are heterogeneous and influenced by healthcare infrastructure, reimbursement mechanisms, and surgical practice patterns across major global markets. In the Americas, adoption is shaped by advanced urological practice, significant outpatient procedural volumes, and payer scrutiny that emphasizes long-term outcomes and cost-effectiveness. Clinicians in this region often lead in generating comparative clinical evidence and establishing best-practice surgical protocols, which in turn influences commercial strategies and product positioning.

Europe, Middle East & Africa presents a diverse landscape where centralized reimbursement decisions in some countries contrast with fragmented payer systems in others. Procurement cycles and hospital purchasing strategies differ markedly, requiring tailored market access plans and acute attention to regulatory harmonization and post-market requirements. Training programs and registry participation are often critical levers for establishing clinical credibility in this region.

Asia-Pacific encompasses markets with rapidly expanding surgical capacity, growing demand for minimally invasive and outpatient procedures, and increasing investments in local manufacturing and regulatory maturity. The region's heterogeneity also means that device sponsors must calibrate pricing strategies and distribution partnerships to local procurement norms, hospital networks, and rising patient awareness of advanced continence interventions. Across all regions, the interplay of clinical evidence, cost considerations, and distribution effectiveness determines the pace and pattern of adoption.

Key company-level insights that illuminate how clinical evidence, manufacturing strategy, training programs, and strategic partnerships create durable differentiation in the urinary sphincter market

Competitive dynamics among companies operating in the artificial urinary sphincter arena center on differentiation through clinical evidence, device reliability, surgical ergonomics, and integrated support services. Leading firms prioritize long-term outcome data, surgeon training programs, and post-market surveillance to demonstrate durability and safety. In addition, companies investing in minimally invasive implantation techniques and simplified actuation mechanisms can reduce procedure times and broaden the pool of implanting clinicians.

Partnerships and strategic collaborations are increasingly important, with device makers aligning with specialist distributors, health systems, and clinical investigators to accelerate device visibility and generate real-world evidence. Some companies focus on vertical integration to secure supply chain stability and to protect margins, while others opt for agile manufacturing models that allow rapid iteration of design improvements.

Service offerings such as comprehensive surgeon training, patient education resources, and registry participation enhance commercial value propositions and build long-term brand trust among urology communities. Finally, firms that embed clinician feedback into iterative product roadmaps and that can demonstrate tangible reductions in revision rates and complication incidence will be better positioned to secure formulary placements and preferred supplier status within health systems.

Strategic and operational recommendations for device makers and health systems to accelerate adoption, protect margins, and build clinical evidence that drives procurement decisions

Industry leaders should pursue a set of actionable initiatives that align clinical value with sustainable commercial returns and operational resilience. First, prioritize generation of high-quality real-world evidence and patient-reported outcomes through registries and multicenter observational studies to underpin value claims and to support negotiations with payers and hospital procurement teams. Second, optimize device design and packaging to reduce operative time and streamline inventory management, which will resonate with ambulatory surgical centers and high-throughput clinics.

Third, diversify and near-shore supply chains to mitigate tariff exposure, logistics disruption, and component scarcity, thereby protecting margins and ensuring reliable product availability. Fourth, deploy specialized surgeon training programs that shorten learning curves and create clinical champions who can advocate for device adoption within their institutions. Fifth, tailor commercial approaches by end-user segment and regional nuance, ensuring that pricing, reimbursement support, and service models match the procurement practices of Freestanding Ambulatory Surgical Centers, Hospital Affiliated centers, Multispecialty Clinics, Urology Clinics, Private Hospitals, and Public Hospitals.

Finally, integrate digital follow-up tools that collect longitudinal patient outcomes to support safety surveillance and to demonstrate reductions in revision rates and downstream resource utilization. By executing these measures, industry leaders can improve adoption velocity, enhance clinical outcomes, and create defensible commercial positions in a competitive landscape.

Transparent explanation of research approach combining clinical literature synthesis, stakeholder interviews, procedural pathway mapping, and supply chain scenario analysis to support the findings

The research methodology underpinning this report combined systematic literature appraisal, stakeholder interviews, device procedural pathway mapping, and synthesis of regulatory and payer frameworks to create a robust evidence base for analysis. Clinical literature and guideline sources were triangulated with interview insights from implanting surgeons, procurement leaders, and distribution partners to capture real-world decision drivers and operational constraints. Procedural pathway mapping documented site-specific requirements across ambulatory surgical centers, clinics, and hospitals, enabling assessment of device fit and perioperative resource needs.

Supplier and distribution channel analysis examined both direct sales models and distributor ecosystems to evaluate strengths and limitations in training, logistical capacity, and market reach. Regulatory pathway reviews highlighted post-market evidence expectations and surveillance mechanisms that influence product lifecycle planning. Finally, scenario analysis explored the impacts of supply-chain shocks and tariff changes on production strategies and procurement dynamics, which informed actionable recommendations for near-term resilience and long-term strategic positioning.

Concluding synthesis highlighting the critical interplay of clinical evidence, device design, and supply chain resilience that will determine long-term success and patient impact

In conclusion, artificial urinary sphincters remain a clinically vital intervention with evolving opportunities driven by device innovation, evidence generation, and shifting care delivery models. The future trajectory of adoption will hinge on the ability of manufacturers to demonstrate durable clinical outcomes, to design implants that simplify surgical workflows, and to align commercial models with the procurement realities of diverse end-user settings. Tariff pressures and supply-chain risks underscore the need for operational agility and strategic supplier choices to maintain access and competitive positioning.

Clinicians, hospital leaders, and device developers who invest in longitudinal evidence collection, targeted surgeon training, and adaptive distribution strategies will be best positioned to translate technological advances into sustained patient benefit. A disciplined focus on total cost of care, paired with clear communication of outcomes and value, will accelerate acceptance among payers and purchasing committees. Ultimately, success in this space will require coordinated efforts across clinical, regulatory, and commercial functions to ensure that device innovations reach patients reliably and safely, delivering measurable improvements in continence and quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Urinary Sphincters Market, by Type

  • 8.1. Single Component
  • 8.2. Three Component
  • 8.3. Two Component

9. Artificial Urinary Sphincters Market, by Gender

  • 9.1. Female
  • 9.2. Male

10. Artificial Urinary Sphincters Market, by Distribution Channel

  • 10.1. Direct Sales
    • 10.1.1. In House Sales Force
    • 10.1.2. Oem Sales Force
  • 10.2. Distributors
    • 10.2.1. Online Platforms
    • 10.2.2. Third Party Distributors

11. Artificial Urinary Sphincters Market, by Application

  • 11.1. Neurogenic Bladder Dysfunction
  • 11.2. Stress Urinary Incontinence

12. Artificial Urinary Sphincters Market, by End User

  • 12.1. Ambulatory Surgical Centers
    • 12.1.1. Freestanding
    • 12.1.2. Hospital Affiliated
  • 12.2. Clinics
    • 12.2.1. Multispecialty Clinics
    • 12.2.2. Urology Clinics
  • 12.3. Hospitals
    • 12.3.1. Private Hospitals
    • 12.3.2. Public Hospitals

13. Artificial Urinary Sphincters Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Urinary Sphincters Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Urinary Sphincters Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Urinary Sphincters Market

17. China Artificial Urinary Sphincters Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Affluent Medical
  • 18.6. Albyn Medical Ltd.
  • 18.7. Andromeda Medizinische Systeme GmbH
  • 18.8. Anhui Longterm Medical Products Co., Ltd.
  • 18.9. Boston Scientific Corporation
  • 18.10. Coloplast A/S
  • 18.11. CooperSurgical Inc.
  • 18.12. Dualis MedTech GmbH
  • 18.13. GT Urological LLC
  • 18.14. LABORIE Medical Technologies Inc.
  • 18.15. MyoPowers Medical Technologies SAS
  • 18.16. Promedon S.A.
  • 18.17. Rigicon Inc.
  • 18.18. Uromedical AG
  • 18.19. Zephyr Surgical Implants AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SINGLE COMPONENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SINGLE COMPONENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SINGLE COMPONENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THREE COMPONENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THREE COMPONENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THREE COMPONENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TWO COMPONENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TWO COMPONENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TWO COMPONENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY IN HOUSE SALES FORCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY IN HOUSE SALES FORCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY IN HOUSE SALES FORCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY OEM SALES FORCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY OEM SALES FORCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY OEM SALES FORCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY NEUROGENIC BLADDER DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY NEUROGENIC BLADDER DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY NEUROGENIC BLADDER DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY STRESS URINARY INCONTINENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY STRESS URINARY INCONTINENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY STRESS URINARY INCONTINENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FREESTANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FREESTANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY FREESTANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITAL AFFILIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITAL AFFILIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITAL AFFILIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY MULTISPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ARTIFICIAL URINARY SPHINCTERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)